| Primary |
| Mycobacterium Avium Complex Infection |
12.2% |
| Pulmonary Tuberculosis |
12.2% |
| Atypical Mycobacterial Infection |
10.8% |
| Hiv Infection |
10.8% |
| Prophylaxis |
8.1% |
| Tuberculosis |
6.8% |
| Helicobacter Gastritis |
5.4% |
| Mycobacterial Infection |
5.4% |
| Acquired Immunodeficiency Syndrome |
4.1% |
| Antiretroviral Therapy |
4.1% |
| Helicobacter Infection |
4.1% |
| Peritoneal Tuberculosis |
4.1% |
| Influenza |
2.7% |
| Lymph Node Tuberculosis |
2.7% |
| Sepsis |
2.7% |
| Antibiotic Therapy |
1.4% |
| Gastrointestinal Disorder |
1.4% |
| Hypertension |
1.4% |
|
| Pyrexia |
9.5% |
| Toxic Skin Eruption |
9.5% |
| Transaminases Increased |
9.5% |
| Alanine Aminotransferase Increased |
4.8% |
| Neutropenia |
4.8% |
| Optic Neuritis |
4.8% |
| Overdose |
4.8% |
| Rash |
4.8% |
| Rash Pruritic |
4.8% |
| Renal Failure Acute |
4.8% |
| Rhabdomyolysis |
4.8% |
| Swelling |
4.8% |
| Synovitis |
4.8% |
| Tendon Rupture |
4.8% |
| Urticaria |
4.8% |
| Vision Blurred |
4.8% |
| Visual Field Defect |
4.8% |
| Vomiting |
4.8% |
|
| Secondary |
| Drug Use For Unknown Indication |
25.5% |
| Hiv Infection |
25.5% |
| Product Used For Unknown Indication |
12.9% |
| Tuberculosis |
7.1% |
| Atypical Mycobacterial Infection |
5.3% |
| Mycobacterium Avium Complex Infection |
5.0% |
| Acquired Immunodeficiency Syndrome |
2.9% |
| Infection |
2.6% |
| Mycobacterial Infection |
2.4% |
| Pulmonary Tuberculosis |
1.6% |
| Cryptococcosis |
1.3% |
| Fungal Infection |
1.3% |
| Antifungal Prophylaxis |
1.1% |
| Lung Disorder |
1.1% |
| Antiretroviral Therapy |
0.8% |
| Lung Infection |
0.8% |
| Peritoneal Tuberculosis |
0.8% |
| Rheumatoid Arthritis |
0.8% |
| Supplementation Therapy |
0.8% |
| Autoimmune Thrombocytopenia |
0.5% |
|
| Pyrexia |
18.0% |
| Neutropenia |
13.1% |
| Vomiting |
8.2% |
| Immune Reconstitution Syndrome |
6.6% |
| Pancytopenia |
6.6% |
| Uveitis |
6.6% |
| Pulmonary Fibrosis |
4.9% |
| Septic Shock |
4.9% |
| Subdural Haematoma |
4.9% |
| Urticaria |
4.9% |
| Fracture |
3.3% |
| Thrombocytopenia |
3.3% |
| Vision Blurred |
3.3% |
| Convulsion |
1.6% |
| Microtia |
1.6% |
| Rash Maculo-papular |
1.6% |
| Renal Failure |
1.6% |
| Respiratory Distress |
1.6% |
| Spleen Disorder |
1.6% |
| Synovitis |
1.6% |
|
| Concomitant |
| Hiv Infection |
29.6% |
| Drug Use For Unknown Indication |
13.4% |
| Mycobacterium Avium Complex Infection |
11.5% |
| Disseminated Tuberculosis |
6.6% |
| Tuberculosis |
6.2% |
| Product Used For Unknown Indication |
6.0% |
| Antifungal Prophylaxis |
3.8% |
| Atypical Mycobacterial Infection |
3.4% |
| Fungal Infection |
2.6% |
| Hypertension |
2.3% |
| Immune Reconstitution Syndrome |
1.9% |
| Supplementation Therapy |
1.9% |
| Insomnia |
1.7% |
| Mycobacterial Infection |
1.5% |
| Respiratory Tract Infection |
1.5% |
| Pain |
1.3% |
| Prophylaxis |
1.3% |
| Anaemia |
1.1% |
| B-cell Lymphoma |
1.1% |
| Cytomegalovirus Infection |
1.1% |
|
| Subdural Haematoma |
27.5% |
| Pancreatitis Acute |
11.8% |
| Hepatitis Fulminant |
7.8% |
| Renal Tubular Disorder |
5.9% |
| Tuberculosis Liver |
5.9% |
| Vomiting |
5.9% |
| Rash Generalised |
3.9% |
| Renal Failure |
3.9% |
| Renal Failure Chronic |
3.9% |
| Rhabdomyolysis |
3.9% |
| Cholestasis |
2.0% |
| Chromaturia |
2.0% |
| Cytolytic Hepatitis |
2.0% |
| Fanconi Syndrome Acquired |
2.0% |
| Hepatotoxicity |
2.0% |
| Hypokalaemia |
2.0% |
| Immune Reconstitution Syndrome |
2.0% |
| Insomnia |
2.0% |
| Neutropenia |
2.0% |
| Paraesthesia |
2.0% |
|
| Interacting |
| Product Used For Unknown Indication |
25.0% |
| Atypical Mycobacterial Infection |
19.6% |
| Mycobacterium Avium Complex Infection |
17.9% |
| Mycobacterial Infection |
16.1% |
| Acquired Immunodeficiency Syndrome |
10.7% |
| Prophylaxis |
7.1% |
| Infection Prophylaxis |
3.6% |
|
| Uveitis |
55.6% |
| Drug Interaction |
11.1% |
| Erythema |
11.1% |
| Iridocyclitis |
11.1% |
| Overdose |
11.1% |
|
